-
Mashup Score: 1
In these prespecified exploratory analyses, there was no significant difference in pain or HRQOL when olaparib was added to abiraterone. In this phase 2 trial, a statistically significant radiographic progression-free survival benefit was observed with the olaparib plus abiraterone combination. These results suggest that the improved survival benefits observed when combining olaparib with…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In these prespecified exploratory analyses, there was no significant difference in pain or HRQOL when olaparib was added to abiraterone. In this phase 2 trial, a statistically significant radiographic progression-free survival benefit was observed with the olaparib plus abiraterone combination. These results suggest that the improved survival benefits observed when combining olaparib with…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: #Patientreportedoutcomes with #olaparib plus #abiraterone versus placebo plus abiraterone for metastatic castration-resistant #prostatecancer: a randomised, double-blind, phase 2 trial https://t.co/cE6iWmtYfd https://t.co/ZFvnTkGlvX
-
-
Mashup Score: 0Prostate cancer - The Institute of Cancer Research, London - 2 year(s) ago
Our researchers are renowned for their success in improving treatments for men with prostate cancer.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our research is helping men with #ProstateCancer live longer. We discovered the drug #Abiraterone and are developing new ways of treating and diagnosing prostate cancer - including #GeneticTesting and new forms of #Radiotherapy ⬇️ https://t.co/4HSSP3u65Z #MensHealthWeek2022 https://t.co/Z8vTj0giMt
-
-
Mashup Score: 1
“This study really showed that we went now beyond 2 years for radiographic progression-free survival, which is the longest we’ve ever seen in the first-line setting,” says Fred Saad, MD, FRCS.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Study assesses the safety and efficacy of olaparib/abiraterone combo in mCRPC https://t.co/wJ8EdYHd2Y @chumontreal @CRCHUM #MCRPC #ProstateCancer #Urology #Urologist #Olaparib #Abiraterone
-
-
Mashup Score: 0
Findings from the phase 3 MAGNITUDE trial showed that adding niraparib to abiraterone acetate significantly extended radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Niraparib plus abiraterone delays mCRPC progression, study finds https://t.co/sZbVB3VAdI #Niraparib #Abiraterone #ProstateCancer #Urology #Urologist #GU22
-
-
Mashup Score: 1
Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading, could halve the risk of death from the disease.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
#Abiraterone could halve risk of #prostatecancer death for some patients @icrnews @TheLancet https://t.co/l3A7QClgN8
-
-
Mashup Score: 3Clinical Outcomes and Racial Disparities in Metastatic Hormone‐Sensitive Prostate Cancer in the Era of Novel Treatment Options - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Clinical Outcomes and Racial Disparities in Metastatic Hormone‐Sensitive Prostate Cancer in the Era of Novel Treatment Options #ProstateCancer #RacialDisparities #UpfrontTherapy #Abiraterone #Docetaxel https://t.co/aIqHmI9cy6 https://t.co/zFiHi5ZwYy
-
-
Mashup Score: 5
Despite the use of an active and established therapy as the comparator, apalutamide plus abiraterone–prednisone improved radiographic progression-free survival. Additional studies to identify subgroups of patients who might benefit the most from combination therapy are needed to further refine the treatment of mCRPC.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Now in the Nov issue: ph 3 ACIS trial on #apalutamide plus #abiraterone acetate vs placebo plus abiraterone in #mCRPC #ProstateCancer https://t.co/upLd7NF9s7
-
-
Mashup Score: 2Circulating and intra-tumoral adrenal androgens correlate with response to abiraterone in men with castration resistant prostate cancer - 3 year(s) ago
Purpose. In metastatic castration resistant prostate cancer (mCRPC) low serum androgens prior to starting Abiraterone Acetate (AA) is associated with more rapid progression. We evaluated the effect of AA on androgens in CRPC metastases and associations of intratumoral androgens with response. Experimental Design. We performed a phase II study of AA plus prednisone in mCRPC. The primary outcome…
Source: Clinical Cancer ResearchCategories: Latest Headlines, UrologyTweet-
Great study just out led by Elahe Mostaghel, Bruce Montgomery and @SeattleCCA group on adrenal androgens and #abiraterone response. Major takeaway is that abi response is associated w/pretx androgens. https://t.co/HcqZ3lpDNW
-
-
Mashup Score: 2
The Institute of Cancer Research, London, is disappointed at the decision by NICE not to recommend abiraterone as a first-line NHS treatment for newly diagnosed, advanced prostate cancer.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We are disappointed at NICE's decision not to recommend abiraterone as a first-line NHS treatment for newly diagnosed, advanced #ProstateCancer. #Abiraterone offers an improvement in quality of life compared with chemotherapy or hormone therapy alone. https://t.co/DcEakolySd https://t.co/sWVUbscdXb
-
Now in the Oct issue: #Patientreportedoutcomes with #olaparib plus #abiraterone versus placebo plus abiraterone for metastatic castration-resistant #prostatecancer: a randomised, double-blind, phase 2 trial https://t.co/cE6iWmcnnF